Clene Inc. (NASDAQ: CLNN) Announces Updates on ACT-EAP for

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
283
Clene Inc. (NASDAQ: CLNN) Announces Updates on ACT-EAP for CNM-Au8(R) Compassionate Use

- Clene announced significant updates to their NIH-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8(R) compassionate use in amyotrophic lateral sclerosis (“ALS”)
- Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants
- The ACT-EAP, a collaboration among Clene, Columbia University, and Synapticure, was funded by the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS), signed into law by Congress and President Biden in December 2021

Clene (NASDAQ: CLNN) and its subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS and multiple sclerosis (“MS”), recently announced significant updates to their ACT-EAP for CNM-Au8 compassionate use in ALS (https://nnw.fm/VZW1Z ).

ALS is a fatal neurodegenerative disease with no known cure, making accessibility to treatment programs crucial. Recognizing this need, Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants.

In collaboration with Columbia University and Synapticure, Clene has secured a four-year grant totaling around $45m from the National Institute of Neurological Disorders and Stroke (“NINDS”), part of the NIH, to support an Expanded Access Program (“EAP”) for their investigational drug CNM-Au8 in ALS.

EAPs, also known as compassionate use programs, are FDA-regulated pathways that allow individuals with serious and life-threatening diseases to access investigational drugs not yet approved by the Food and Drug Administration. Funding for EAPs in ALS was strengthened by the ACT for ALS, signed into law by Congress and President Biden in December 2021.

Rob Etherington, CEO of Clene, said CNM-Au8 treatment has been associated with lowered risk of death and delayed clinical worsening, while being very well-tolerated in both of the company’s independent Phase 2 clinical studies. “Data from EAP programs, which usually include a broader ALS population than clinical trials, can supplement the safety and other meaningful data gathered from clinical studies,” Etherington added. “We are grateful for the NIH’s recognition to fund this important initiative and are pleased to provide this EAP for the ALS community. We are also grateful to the FDA for approving this EAP, working alongside Columbia University and Synapticure, to enable people who are living with this devastating disease access to our investigational drug CNM-Au8.”

Clene’s ACT-EAP is designed not only to meet FDA safety standards for EAPs but also to contribute valuable research data on ALS disease progression and therapy response. The program’s additional objectives include collecting real-world drug exposure data to enhance the CNM-Au8 clinical safety database and monitoring drug efficacy on survival and disease progression using natural history and control clinical trial database comparators. Biomarker data will also be collected and analyzed. This study is supported by the NIH under grant 1U01NS136023-01.

Dr. Jinsy A. Andrews, MD, MSc, FAAN, of Columbia University, and Principal Investigator on the grant, underscored that this was not just a standard EAP, in which Clene provides the investigational product to individuals with ALS through an FDA-regulated program. “A lot of time, careful thought, and effort have resulted in a study that will yield important insights into the real-world impact of CNM-Au8 treatment on the disease course of ALS,” Andrews explained.

The first patient visit for the ACT-EAP is scheduled for June 2024.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

Clene Inc. (CLNN) Stock Research Links

CLNN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 18

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 200

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 95

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 29

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 17

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 136

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 177

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Kelly Munson Takes Charge as President and CEO of Independence Health Group

Updated Category News Views 574

Kelly Munson Appointed President and CEO Independence Health Group proudly announces that Kelly A. Munson will take the role of President and Chief Executive Officer. Beginning this new chapter, she will bring with her a wealth of experience and insight derived from her tenure with AmeriHealth Caritas, which operates under the Independence Health Group umbrella....

Continue Reading
Seek AI Achieves Dual Patents, Pioneering AI Data Workflows

Updated Category News Views 201

Innovative Patents Transforming AI Data Analytics NEW YORK-- Seek AI, the agentic AI platform designed for the modern data stack, proudly announces the acquisition of two groundbreaking patents. Awarded by the United States Patent and Trademark Office (USPTO), these patents highlight Seek AI's unique approach to human-in-the-loop workflows that utilize LLM-generated...

Continue Reading
InMed Pharmaceuticals Tackles Nasdaq Compliance Challenges

Updated Category News Views 95

InMed Pharmaceuticals Faces Nasdaq Compliance Challenge InMed Pharmaceuticals Inc. (NASDAQ: INM), a biopharmaceutical firm recognized for its innovative drug development, is actively addressing a delisting notice from Nasdaq, which is due to not meeting minimum bid price regulations. The company has formally initiated an appeal to the Nasdaq Listing Qualifications Panel...

Continue Reading
Tetragon Financial Group Investor Call Highlights and Insights

Updated Category News Views 139

Join Tetragon Financial Group for a Special Investor Call Tetragon Financial Group Limited will be hosting an important investor call to provide key updates about the company. Set for Wednesday, March 5, at 15:30 GMT / 10:30 EST, this call is a significant opportunity for investors to gain insights into Tetragon's annual report and overall company performance. What to...

Continue Reading
Exploring the Future of Bleeding Disorders Treatment Market

Updated Category News Views 214

Growing Landscape of the Bleeding Disorders Treatment Market The Bleeding Disorders Treatment Market is on a significant growth trajectory as it adapts to the rising global prevalence of conditions like hemophilia and other rare coagulation disorders. This upward trend is supported by remarkable advancements in treatment options, increasing healthcare funding, and rising...

Continue Reading